Scope Fluidics S.A.

Warsaw Stock Exchange SCP.WA

Scope Fluidics S.A. Capital Expenditure for the year ending December 31, 2023: USD -489.18 K

Scope Fluidics S.A. Capital Expenditure is USD -489.18 K for the year ending December 31, 2023, a -65.12% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Scope Fluidics S.A. Capital Expenditure for the year ending December 31, 2022 was USD -296.26 K, a 75.61% change year over year.
Scope Fluidics S.A. Capital Expenditure for the year ending December 31, 2021 was USD -1.21 M, a -838.03% change year over year.
Scope Fluidics S.A. Capital Expenditure for the year ending December 31, 2020 was USD -129.49 K, a -44.29% change year over year.
Scope Fluidics S.A. Capital Expenditure for the year ending December 31, 2019 was USD -89.74 K, a -331.38% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Warsaw Stock Exchange: SCP.WA

Scope Fluidics S.A.

CEO	Mr. Piotr Garstecki
IPO Date	Aug. 1, 2017
Location	Poland
Headquarters	9th floor
Employees	40
Sector	Healthcare
Industries Biotechnology Medical Instruments

Description

Scope Fluidics S.A., a biotechnology company, engages in the designing and developing projects based on microfluidic technologies in medical diagnostics and healthcare. It offers BacterOMIC, an antibiotic susceptibility testing. The company was founded in 2010 and is based in Warsaw, Poland.

Key trends

Past 5 years